YEXT - Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session | Benzinga
Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares.
GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from Benzinga Pro.
GameStop shares dipped 22.5% to $36.07 on Friday.
Here are some other stocks moving in today’s mid-day session.
Gainers
- Trinity Place Holdings Inc. (NYSE:TPHS) jumped 165.4% to $0.3220 after declining around 11% on Thursday.
- Leafly Holdings, Inc. (NASDAQ:LFLY) shares gained 91.6% to $3.87.
- Venus Concept Inc. (NASDAQ:VERO) shares jumped 87.5% to $1.1606 on continued upward momentum after the stock regained Nasdaq compliance.
- Asensus Surgical, Inc. (NASDAQ:ASXC) climbed 40.1% to $0.3291 after the company announced it will be acquired by KARL STORZ for $0.35 per share in cash.
- Faraday Future Intelligent Electric Inc. (NASDAQ:FFIE) gained 29.3% to $0.7032.
- Geron Corporation (NASDAQ:GERN) shares jumped 26% to $4.90 as the company reported the FDA approval of RYTELO™ (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
- China Liberal Education Holdings Limited (NASDAQ:CLEU) gained 23.4% to $2.4899.
- American Oncology Network, Inc. (NASDAQ:AONC) gained 22.6% to $2.0850. American Oncology Network recently announced the opening of Low Country Radiation in Waycross, Georgia.
- MAIA Biotechnology, Inc. (NASDAQ:MAIA) rose 21.2% to $4.0249. The company unveiled compelling efficacy data from its Phase 2 THIO-101 clinical trial.
- ChromaDex Corporation (NASDAQ:CDXC) gained 19.2% to $3.41 after the company received exclusive ...